Among adults with chronic rhinosinusitis with nasal polyps who endured endoscopic sinus surgery, those with severe vs. mild ...

Type 2 CRSwNP is linked to worse health-related quality of life, with higher rates of smell loss and rhinorrhea emerging as ...

French pharma major Sanofi and US partner Regeneron Pharmaceuticals yesterday presented positive results from the EVEREST ...

In the EVEREST trial, 360 adults with severe, uncontrolled CRSwNP and coexisting asthma were randomized to receive Dupixent 300 mg (n=181) every two weeks or a weight- and immunoglobulin E (IgE ...

According to the ACTIONS study, 39% of patients with chronic rhinosinusitis with nasal polyps (CRSwNP) faced overexposure to ...

Dupixent demonstrated superior efficacy in reducing nasal polyp size and improving smell in CRSwNP, as well as enhancing lung function and disease control in asthma, with benefits observed as ...

Pharmacology modeling data presented at the European Academy of Allergy & Clinical Immunology (EAACI) Congress describe ...

New late-breaking data at EAACI showed Dupixent outperformed Xolair across all primary and secondary efficacy endpoints of CRSwNP and in all asthma-related endpoints Dupixent also outperformed ...

In patients with chronic rhinosinusitis with nasal polyps, factors including baseline antibiotic use and asthma impacted the ...

According to the ACTIONS study, 39% of patients with chronic rhinosinusitis with nasal polyps (CRSwNP) faced overexposure to oral corticosteroids (OCS) before beginning biologic therapy.

The second indication is as an add-on maintenance treatment of adult patients with inadequately controlled chronic rhinosinusitis with nasal polyps (CRSwNP). The NDS is based on data from the positive ...